Invesco S&P 500 Momentum ETF (SPMO) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- Broad Market / FactorSector
- $161.6652W High
- $107.8452W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track Invesco S&P 500 Momentum ETF (SPMO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Invesco S&P 500 Momentum ETF has traded between a low of $107.84 and a high of $161.66, highlighting its annual price range. Buy and sell Invesco S&P 500 Momentum ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Most Recent News
NewHydrogen plans to use nuclear heat to produce clean hydrogen at industrial scale, bypassing costly electricity use.
NewHydrogen announced its plan to pair its ThermoLoop technology with heat from small modular nuclear reactors (SMRs) to produce clean hydrogen at industrial scale. This approach uses high-temperature nuclear heat to split water thermochemically, avo...

Altisource CEO buys shares amid 19% revenue rise and AI-driven efficiency boost
Altisource Portfolio Solutions' CEO Shepro William B purchased 4,000 shares, increasing his stake to 8,686 shares, signaling confidence in the company's future. The company reported a 19% year-over-year increase in Q2 2026 service revenue to $48.70 m...

Access barriers limit Xphozah uptake despite nephrologists' willingness to triple use, with reimbursement changes ahead.
New research from Spherix Global Insights reveals that access barriers, not drug efficacy, restrict the use of Ardelyx's Xphozah for dialysis patients with hyperphosphatemia. Nephrologists say they would nearly triple Xphozah prescriptions if reimbur...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.